Breaking News

Financial Report: Charles River Laboratories

August 7, 2014

Manufacturing revenue up 18% in the quarter

Charles River Laboratories

2Q Revenues: $341.2 million (+16%)

2Q Earnings: $35.3 million (+29%)

YTD Revenues: $640.5 million (+8%)

YTD Earnings: $67.5 million (+28%)

Comments: Revenue for the Research Models and Services (RMS) segment was $133.1 million in the quarter, up 3%. Discovery and Safety Assessment (DSA) revenue was $142.6 million, up 33% in quarter driven by the acquisition of Argenta and BioFocus, which contributed 22% to DSA revenue. Revenue for the Manufacturing segment was $65.4 million in the quarter, up 18% with growth across all businesses, including a double-digit growth rate for both the Endotoxin and Microbial Detection, and Biologics Testing Solutions businesses.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks